Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investing in Unpredictable Times: A Conversation with Biotech-CEO-Turned-VC David Mott

This article was originally published in RPM Report

Executive Summary

Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.

You may also be interested in...



The State of New Drug Reviews in the US

Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.

The State of New Drug Reviews in the US

Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.

Orphan Drugs Plus REMS: A Perfect Fit?

Biopharma companies have a decidedly mixed view of FDA's new post-marketing safety authorities. But for one industry segment-companies concentrating in serving very small patient populations suffering from rare diseases-the new regulatory model is decidedly good for business. What does that mean for the future of Big Pharma?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel